




Certificate of Mailing (37 C.F.R. §1.10):

I hereby certify that this correspondence is being deposited with the United States Postal Service Express Mail (EV 723989573) in an envelope addressed to: Mail Stop ISSUE FEE, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on this 22th day of July 2005.

s/   
Christina M. Compelube

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re the Application of:**  
**Suzanne Benedict, et al.**

**Serial No.:** 10/754,171

**Filed:** January 9, 2004

**Confirmation No.:** 8481

**For:** TRICYCLIC COMPOUNDS PROTEIN  
KINASE INHIBITORS FOR  
ENHANCING THE EFFICACY OF ANTI-  
NEOPLASTIC AGENTS AND  
RADIATION THERAPY

**Group Art Unit:** 1625

**Examiner:** Charanjit Aulakh

**Attorney Docket No.:** PC25144A

Mail Stop: ISSUE FEE  
Honorable Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Transmitted herewith are the following documents:

1. Form PTOL-85	1 Page + Duplicate;
2. Return Postcard	1 Postcard; and
3. Comments on Statement of Reason for Allowance	2 pages
4. Total Fee Due	Deposit Account.

Respectfully submitted,

Date: July 22, 2005

  
Ye Hua  
Agent For Applicants  
Registration No. 53,042

Agouron Pharmaceuticals, Inc./A Pfizer Company  
Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 622.3020  
Fax: (858) 678-8233

PC25144A

Comments on Reason for Allowance of Appln. No.  
10/754,171



Certificate of Mailing (37 C.F.R. §1.10):

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (EV 723989573 US) in an envelope addressed to: Mail Stop AMENDMENT, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 22<sup>th</sup> day of July 2005.

s/   
Christina M. Compelube

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

<b>In re the Application of:</b> Benedict, et al.	<b>Group Art Unit:</b> 1625
<b>Serial No.:</b> 10/754,171	<b>Examiner:</b> Aulakh, Charanjit
<b>Confirmation No.:</b> 8481	
<b>Filed:</b> January 9, 2004	<b>Attorney Docket No.:</b> PC25144A
<b>For:</b> TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY	

Mail Stop ISSUE FEE  
Honorable Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**COMMENTS ON STATEMENT OF REASON FOR ALLOWANCE**

Sir:

In response to the Notice of Allowance mailed June 30, 2005, Applicants herein make the following comments on statement of reason for allowance.

**Comments** begin on page 2 of this paper.

Comments

The Examiner stated on page 2 of the Notice of Allowance that the reasons for allowance are that "applicants have either canceled or amended claims to overcome enablement, indefiniteness and prior art rejections and therefore, all 35 U.S.C. 112, first and second paragraph was well as under 35 U.S.C. 102(b) are now withdrawn".

Applicants would like to restate that Applicants do not acquiescence to the merits of the 102(b) prior art rejection of claims 1, 2, 18-21, 24, 27-31, and 33-45 made by the Examiner regarding reference Webber (WO 00/42040). Claim 1 was amended to expedite prosecution.

Applicants would like to further state that Applicants do not acquiescence to the merits of enablement and indefiniteness rejection of 35 U.S.C. 112 first paragraph and second paragraph of claims 2, and 33-45. Claims 2 and 33-45 were canceled to expedite prosecution.

If any fees other than those submitted herewith are due in connection with this response, please charge such fees to Deposit Account No. 500329.

Respectfully submitted,

Date: July 22, 2005

  
\_\_\_\_\_  
Ye Hua  
Agent For Applicants  
Registration No. 53,042

Agouron Pharmaceuticals, Inc./A Pfizer Company  
Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 622-3020  
Fax: (858) 678-8233